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Recombinant human erythropoietin enhances superoxide
production by FMLP-stimulated polymorphonuclear leukocytes in
hemodialysis patients
HUNG-CHUN CHEN, JER-CHL4 TsM, JuEI-HsIuNG TsM, and YUNG-HSIUNG LM
Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical College, Kaohsiung, Taiwan, Republic of China
Recombinant human erythropoietin enhances superoxide production
by FMLP-stimulated polymorphonuclear leukocytes in hemodialysis pa-
tients. Recombinant human eiythropoietin (rHuEPO) is a hematopoietic
growth factor that has a broad spectrum of action. We have observed the
in vivo and in vitro effects of rHuEPO on the superoxide production of
circulating polymorphonuclear leukocytes (PMNs) in hemodialysis pa-
tients. The PMNs were separated from heparinized blood after dextran
sedimentation and Ficoll-Conray centrifugation and stimulated with
formyl-methionyl-leucyl-phenylalanine (FMLP), serum-treated zymosan
(STZ), or phorbol myristate acetate (PMA). The in vivo study showed that
rHuEPO therapy for 12 weeks enhanced the superoxide production by
FMLP-stimulated PMNs (P < 0.01). However, no significant changes on
superoxide production was found in either STZ- or PMA-stimulated
PMNs. Simultaneous measurement of PGE2 production by PMNs in
response to all three stimulants did not show any significant changes after
rHuEPO therapy. The direct lfl Vitro effect of rHuEPO on PMNs showed
that rHuEPO does not enhance the superoxide production by non-
stimulated PMNs. However, preincubation of rHuEPO enhanced super-
oxide production from FMLP- and STZ-stimulated PMNs. Our results
indicate that rHuEPO enhanced FMLP-stimulated superoxide production
of PMNs both in vivo and in vitro in hemodialysis patients, which may be
responsible for the increased oxidant stress in hemodialysis patients after
rHuEPO therapy.
Recombinant human erythropoietin (rHuEPO) has been devel-
oped for correcting the anemia of patients with end-stage renal
disease (ESRD). However, several clinical studies have demon-
strated that rHuEPO is a multipotential hemopoietic growth
factor both in vitro and in vivo [1—3], and also has some specific
effects on the immune system [4, 5]. Pfaffl et a! found a decrease
in the suppressor T cell subpopulation and an increase in helper!
suppressor ratio of T cell [4], and Paczek, Schaefer and Heidland
reported an increased immunoglobulin production by peripheral
blood mononuclear cells in hemodialysis patients after rHuEPO
therapy [5]. rHuEPO also modulates the production of neutro-
phils [6, 7] and corrects platelet function in uremic patients [8].
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However, there have been no studies on the effects of rHuEPO on
polymorphonuclear leukocyte (PMN) function until now.
Several investigators have suggested that hemodialysis (HD)
treatment leads to activation of neutrophils with the release of
large amounts of toxic oxygen free radicals [9—12], and rHuEPO
has been suspected to be responsible for the increased oxidative
injury to erythrocytes in HD patients [13]. Whether rHuEPO
affects the activation of PMNs is not known. Therefore, the
present study was designed to investigate the effects of rHuEPO
therapy on the production of the active oxygen free radical, the
superoxide anion, by circulating PMNs in HD patients. To further
elucidate the possible effects of rHuEPO on PMNs, we also
measured the direct in vitro effect of rHuEPO on the superoxide
production in these patients.
METHODS
Patients
The study included 15 stable patients who were undergoing
regular hemodialysis therapy. There were no signs of infection
and no patient was receiving corticosteroid or nonsteroid anti-
inflammatory drugs at the time of examination. The age was 46
11 (mean SD) years old and included 9 males and 6 females. The
mean duration on hemodialysis was 47 40 months. Twenty
apparently normal subjects served as normal controls. Their mean
age was 42 12 years old and included 8 males and 12 females.
The protocol was approved by the Committee of Medical Ethics
in Kaohsiung Medical College Hospital, and all patients gave
informed consent.
Polymorphonuclear leukocyte separation
Leukocyte suspension were prepared by means of Ficoll-Con-
ray gradients [11, 14, 15]. Briefly, heparinized (20 U!ml) venous
blood was left at room temperature for 30 minutes after adding
normal saline and 5% Dextran-0.9% NaC1 solution. The PMNs
layer was then aspirated to a 10% Ficoll-60% Conray solution and
certrifuged. The pellet was washed with phosphate buffer saline
(PBS) and then underwent hypotonic lysis of erythrocytes. The
PMNs obtained by this method were resuspended in PBS for
study. This method allowed the purity of PMNs to be as high as
95 3% (N = 40) without significant contamination of erythro-
cytes and platelets. Cell viability was tested using trypan blue
exclusion test, which revealed a 97 3% viable cell count.
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Preparation of stimulants
All the chemicals used below were purchased from Sigma
Chemical Co. (St. Louis, MO, USA) unless stated otherwise.
FMLP was dissolved in dimethylsulfoxide (DMSO) at a concen-
tration of io— M and stored at —20°C. Zymosan was boiled and
washed twice with 0.85% NaCI and then incubated with fresh,
normal serum at a concentration of 10 mg/mi for 30 minutes at
37°C. After centrifugation and two washings, this preparation of
serum-treated zymosan (STZ) was suspended in buffer at a
concentration of 5 mg/ml. PMA was dissolved in DMSO at a
concentration of 33.3 j.tg/ml and stored at —80°C. After establish-
ing a standard dose-response curve, the optimal final concentra-
tion used for stimulation was 106 M for FMLP, 500 .tg/mi for
STZ, and 80 ng/mi for PMA. The final concentration for DMSO
was less than 0.1%, a concentration that would not interfere with
PMNs function.
In vivo effect of erythropoietin on polymorphonuclear leukocytes
The superoxide anion and prostaglandin E2 (PGE2) production
of circulating PMNs after various stimulation were measured
before and after 12 weeks of rHuEPO therapy in hemodialysis
patients. rHuEPO was given intravenously either twice or three
times a week in doses ranging from 30 to 120 U/kg each time with
a target hematocrit level of 30%. All the HD prescriptions,
including the dialyzers used, time and blood flow, did not change
during the treatment period, showing that they did not contribute
to any beneficial effect.
In vitro effect of erythropoietin on polymorphonuclear
leukocytes
To determine the direct effect of rHuEPO on PMNs, we
measured the production of superoxide and PGE2 in vitro in the
presence or absence of rHuEPO (2.0 U/mi) by stimulating PMNs
isolated from those HD patients before treatment with rHuEPO
and in normal controls. The isolated PMNs were preincubated
with rHuEPO at 37°C for 30 minutes before stimulation. To
obtain the dose-response curve, rHuEPO was added at concen-
trations of 0.05, 0.1, 0.5, 1.0, 2.0 and 5.0 U/mi, respectively. The
final concentration used for study was 2.0 U/mi. The effect of
rHuEPO on non-stimulated PMNs was also measured.
Superoxide anion measurement
Superoxide anion production by PMNs was determined by
measuring superoxide dismutase-inhibitable reduction of cyto-
chrome C by spectrophotometer, which was a method modified
from Barbior et al [151. The PMNs (containing io cells/ml) in
PBS containing Ca2 (1 mM) and cytochrome C (80 M) with or
without superoxide dismutase (500 ig/m1) were preincubated for
five minutes in a 37°C water bath. The PMNs were then stimu-
lated with FMLP, STZ and PMA, respectively, at 37°C for 10
minutes in a shaking water bath, and the reaction was terminated
10 minutes later by putting them on ice. The absorbance was then
measured by spectrophotometer at 550 nm.
Prostaglandin E2 measurement
The PGE2 was extracted from the supernatant and then mea-
sured using a radioimmunoassay kit (Amersham, USA). Briefly,
the samples were purified after adding ethanol and glacial acetic
acid and then centrifuged. The supernatant was applied to C18
Table 1. Results of recombinant human erythropoietin (rHuEPO)
therapy for 12 weeks in hemodialysis patients
Before therapy After therapy P value
RBC x104/1.d 208 35 304 38 <0.001
Hb gIdi 6.4 1.2 9.5 1.5 <0.001
Hct % 9.2 3.6 28.6 4.4 <0.001
WBC X1031p.1 5.33 1.34 5.32 1.34 NS
PLT X1O/pJ 176 52 186 68 NS
BUN mmol/Liter 32.2 6.2 35.0 7.9 NS
Sr timol/liter 1255 230 1264 230 NS
Data are expressed as mean SD.
NS denotes not significant.
Abbreviations are: RBC, red blood cells; Hb, hemoglobin; Hct, hemat-
ocrit; WBC, white blood cells; PLT, platelet count; BUN, blood urea
nitrogen; Se,, serum creatinine.
Sep-pak cartridge. After being washed with water and hexane, the
samples were eluted with ethyl acetate, and then dried with
nitrogen. The extracted samples were reconstituted with methyl
oximation reagents and then analyzed by radioimmunoassay.
Statistics
All data below are expressed as mean SD. Student's paired
and unpaired f-tests were used to compare the differences.
RESULTS
Hemogram and biochemistry
The red blood cell count, hemoglobin and hematocrit increased
significantly after rHuEPO therapy (all P < 0.001; Table 1). There
were no changes in the leukocyte and platelet counts. None of the
serum biochemistries was significantly changed after rHuEPO
therapy. All patients had a greater feeling of well-being.
Superoxide anion production
After stimulation with FMLP, STZ, and PMA, the superoxide
anion production of normal controls was 3.38 0.39, 1.77 0.66,
and 3.70 0.67 nmol/106 PMNs/10 minutes, respectively (Table
2). In hemodialysis patients, the superoxide anion production by
FMLP-stimulated PMNs increased significantly after rHuEPO
therapy (P < 0.01). The increment of superoxide production was
not significantly correlated with the amount of rHuEPO given.
The STZ-stimulated superoxide anion production before
rHuEPO therapy was significantly lower than normal controls
(P < 0.05). After rHuEPO therapy, the value increased and was
no longer lower than that found in the normal controls. The
superoxide anion production by PMA-stimulated PMNs was not
significantly changed after rHuEPO therapy.
Prostaglandin E2 production
After stimulation with FMLP, STZ, and PMA, the PGE2
production of PMNs in normal controls was 25.8 5.2, 17.0 6.6
and 27.4 5.6 pg/tO6 PMNs/10 minutes, respectively (Table 3). In
hemodialysis patients, the PGE2 production, in response to
FMLP, STZ, and PMA, respectively, was not significantly differ-
ent from that found in the normal controls. After ri-IuEPO
therapy, the PGE2 production, in response to FMLP, STZ, and
PMA, respectively, was also not significantly changed compared to
the values before rHuEPO therapy.
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Table 2. Superoxide anion production of PMNs (nmol/106 PMNs/l0
mm) after stimulation with FMLP, STZ, and PMA in hemodialysis
patients before and after rHuEPO therapy
Normal
controls
HD patients
Before rHuEPO After rHuEPO
FMLP 3.38 0.39 2.97 102h
STZ 1.77 0.66 1.37 O.32a
PMA 3.70 0.67 3.51 0.72
4.46 0.90
1.56 0.45
3.42 0.86
Abbreviations are: PMNs, polymorphonuclear leukocytes, FMLP,
formyl-methionyl-leucyl-phenylaline, STZ, serum-treated zymosan; PMA,
phorbol myristate acetate; rHuEPO, recombinant human eiythropoictin;
HD, hemodialysis.
ap < 005 bp < 0.01 compared to normal controls
P < 0.01 compared to data before rHuEPO therapy
In vitro study of the dose-response of rHuEPO on superoxide
and PGE2 production
Significant dose-responsiveness of the superoxide production
was only found in FMLP-stimuiated PMNs, which showed a
significant increase with rHuEPO dosages higher than 1.0 U/mi
(Table 4). There was no dose-responsiveness on PGE2 produc-
tion. When rHuEPO alone was used, the non-stimulated PMNs
did not show any significant production of superoxide.
In vitro effects of rHuEPO on PMN superoxide and PGE2
production
rHuEPO (2.0 U/ml) showed a direct in vitro effect on the
superoxide production of FMLP-stimulated PMNs both in normal
controls (P < 0.01) and in HD patients (P < 0.01; Table 5). No
effects were observed in STZ and PMA-stimulated PMNs.
DISCUSSION
In this study, the administration of rHuEPO effectively stimu-
lated red cell production in hemodialysis patients. An increase of
hematocrit from 19.2% to 28.6% and mean hemoglobin level
from 6.4 g/dl to 9.5 g/dl was achieved with this therapy within 12
weeks.
Anemia of chronic renal failure has generally been attributed to
a combination of multiple factors including EPO deficiency [161,
folate deficiency [17], aluminum toxicity [18], severe osteitis
fibrosa [191, bleeding [20], and the presence of inhibitors for
erythropoiesis [21]. Shortened RBC life survival due to hemolysis
has also been confirmed by some isotopic RBC studies [22, 23],
and hemodialysis therapy has been reported to not significantly
improve RBC survival [24—26]. Different mechanisms have been
implicated in hemolysis of RBC. Among the possibly important
mechanisms are lipid peroxidation of the RBC membrane in-
duced by free radicals, constitutively impaired RBC deformability
and splenic sequestration [24—26]. In a study on rHuEPO therapy
on hemodialysis patients, Zachee et al did not demonstrate any
significant improvement in RBC oxidative sensitivity, RBC de-
formability, and splenic RBC volume despite the significant
improvement of anemia of their patients [13]. Further studies
have shown decreased protective antioxidant enzyme activities in
RBCs of rHuEPO-treated hemodialysis patients [27, 28]. Our
data demonstrate that this failure to improve the erythrocyte
defense mechanisms against oxygen free radicals may due to the
enhanced superoxide production by circulating PMNs after
rHuEPO therapy, and the enhanced superoxide production
Table 3. Prostaglandin E2 production of PMNs (pg/lU6 PMNs/10 mm)
after stimulation with FMLP, STZ, and PMA in hemodialysis patients
before and after rHuEPO therapy
HD patientsNormal
controls Before rHuEPO After rHuEPO
FMLP 25.8 5.2 24.6 5.4 27.0 6.9
STZ 17.0 6.6 15.9 6.5 15.7 7.1
PMA 27.4 5.6 26.1 7.8 23.2 4.5
Ahhreviations are in Table 1.
should at least be partially responsible for the reduced RBC life
span in hemodialysis patients, which persists after rHuEPO
treatment [29—31].
The nature of increased in vivo oxidant stress after rHuEPO
therapy has not been clear. Although hemodialysis treatment has
been suspected to activate the neutrophils with the release of a
large number of toxic oxygen free radicals [9—12], no part of the
hemodialysis condition was changed during our study. A correc-
tion of deficient phagocytosis during rHuEPO treatment in main-
tenance hemodialysis patients has also been found [32], and this
correction has been suspected to he due to factors including better
cellular oxygenation that may provide more substrate for super-
oxide production, and/or improving metabolism of PMNs precur-
sor and PMNs. We have confirmed the hypothesis that rHuEPO
corrects deficient phagocytosis by enhancing the potential for
PMNs to produce superoxide, which is a powerful tool that PMNs
uses to kill microorganisms. The modulating effects of rHuEPO
could also be mediated by cytokines affecting the level of activity
of NADPH oxidase [33], and the correction of iron overload may
also be. related [34]. rHuEPO may also transmodulate the signal-
ing pathway of granulocyte-macrophage colony stimulating factor
(GM-CSF), which can trigger the superoxide production from
human monocytes stimulated with FMLP [35]. The effect of PGE2
was also emphasized because simultaneous production of PGE2
by PMNs may exert cytoprotective action though a suppression of
the generation of superoxide after FMLP stimulation [36, 37].
This effect can be ruled out according to our study since the PGE2
production of PMNs was not significantly changed after rHuEPO
therapy.
We have demonstrated that rHuEPO in vitro enhances the
superoxide production of FMLP-stimulated PMNs. The effect
might be direct or mediated through other cells within the PMN
mix. The mechanisms by which rHuEPO effects the superoxide
production is obscure. Since STZ stimulation involves both
phagocytosis and activation of complement receptors and PMA
stimulation activates protein kinase C, these mechanisms are
apparently riot related to rHuEPO therapy. Whether rHuEPO
receptors are present on PMNs is not known, although many cell
lines have proved to contain rHuEPO receptors [38]. Our data do
not favor the presence of EPO receptors on PMNs, since rHuEPO
alone exerts no effect on the superoxide production of non-
stimulated PMNs. rHuEPO has also been reported to effect on
many hematopoietic cells including megakaryocytes [—31, lym-
phocytes [4], monocytes [51, myeloid series [4] and erythroid series
[1—3], though EPO receptors have not been identified in any of
them.
FMLP is a formylated oligopeptide that is a specific chemoat-
tractant receptor agonist for PMNs. The mechanisms by which
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Table 4. Dose-respnnse at rHuEPO an supernxide (nmol/106 PMNs/10 mm) and POE, (pg/lU6 PMNs/10 mm) production of circulating PMNs
withnut stimulation or stimulated with FMLP, STZ and PMA from five normal controls
0
rHuEPO dosage Clint
0.05 0.1 0.5 1.0 2.0 5.0
Supernxide
Na stimulation 0.19 0.08 0.18 0.09 (1.13 0.04 0.16 (1.10 0.24 0.11 0.14 0.06 0.16 0.10
FMLP stimulation 3.12 0.51 3.41 0.81 3.t8 0.64 3.59 0.97 4.37 0.88' 5.11 1.12' 5.39 1.38'
STZ stimulation 1.71 0.67 1.52 0.81 1.58 0.38 1.84 0.79 1.91 0.82 1.61 0.79 1.79 0.64
PMA stimulation 3.88 0.81 3.59 1.02 3.79 0.97 3.82 0.69 3.64 1.13 3.72 0.68 3.91 0.09
POE2
Na stimulation 5.31 3.98 3.97 1.69 5.12 2.34 2.87 2.38 4.10 2.27 3.66 1.94 4.69 3.55
FMLP stimulation 23.8 7.6 19.5 10.2 28.1 13.9 21.1 6.7 27.1 15.4 20.9 9.8 23.9 12.1
STZ stimulation 18.2 5.8 13.9 9.4 16.8 6.1 15.7 3.9 20.1 7.4 14.2 8.8 19.8 5.9
PMA stimulation 26.4 4.9 31.2 9.1 27.9 5.2 22.9 7.7 26.7 6.9 29.8 8.8 25.1 6.1
Ahbrcviations are in Table 1.
P < 0.01 comparc to 0 U/mI
Table 5. Direct in vitro effects of rHuEPO (2.0 U/mI) on thc
production of superoxide (nmol/106 PMNs/10 mm) and POE2 (pg/I O
PMNs/10 mm) by circulating PMNs isolated from hemodialysis patients
and normal controls, and stimulated with FMLP, STZ and PMA
Normal controls 1-ID patients
rHuEPO(—) rHuEPO(±) rHuEPO(—) rHuEPO(±)
Superoxide
FMLP 3.38 0.39 5.04 0.94' 2.97 1.02 5.29 0.88'
STZ 1.77 0.66 1.49 0.76 t.37 0.32 1.68 0.59
PMA 3.70 0.67 3.98 0.49 3.51 (1.72 3.66 1.02
POE,
FMLP 25.8 5.2 21.4 8.8 24.6 5.4 27.1 9.0
STZ 17.0 6.6 19.8 4.7 15.9 6.5 14.8 7.2
PMA 27.4 5.6 31.2 7.5 26.1 7.8 29.2 5.9
Ahbrcviations are in Table I and: rHuEPO(—), absence of rHuEPO;
rHuEPO(+), prcscncc of rHuEPO.
'P < 0.01 comparcd to rHuEPO(—).
rHuEPO selectively enhances the FMLP-stimulated superoxide
production by PMNs is obscore. It is known that when PMNs are
exposed to agents that affect physical parameters of cell mem-
branes and thos the receptor fonetion, their biological functions
can be differentially modified [39j. Priming the neutrophuls with
heat-aggregated IgA from patients with IgA nephropathy also
rendered the neutrophils more responsive fo the subsequent
stimulation by FMLP [40, 41]. The reason that rHoEPO and
FMLP have a synergistic effect is not known. 1-lowever, the
postreceptor events for both rHuEPO and EMLP are identical in
that both stimulate a transient increase in the enzymatic activity of
cellular mitogen-activated protein kinase [42, 43] and therefore
may have a synergistic effect at the postreceptor level of action.
Furthermore, our results also demonstrate that the relative inef-
fectiveness of rI-IuEPO in patients with infectious status may also
due to the consequence of enhanced superoxide production of the
PMNs in these patients, because priming the PMNs with rHuEPO
rendered the PMNs more responsive to subsequent stimulation by
FMLP, an experimental condition that mimics bacterial infection
in clinical setting.
In sommary, we have demonstrated that rHuEPO enhances the
superoxide production by FMLP-stimulated PMNs in hemodial-
ysis patients, which may he the major source of increased in vivo
oxidant stress and is responsible for the reduced lifespan for RBC
in hemodialysis patients.
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APPENDIX
Abbreviations used in this paper are: rHuEPO, recombinant human
erythropoietin; PMNs, polymorphonuelear leukoeytes; FMLP, formyl-
methionyl-leucyl-phenylalanine; STZ, serum-treated zymosan; PMA,
phorbol myristatc acetate; POE2, prostaglandin F2; HD, hemodialysis;
ESRD, end-stage renal disease; RBC, red blood cell; OM-CSF, granulo-
cyte-macrophage colony stimulating factor.
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